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Abstract
Background: Several studies point to a role of Toll-like receptors (TLRs) in the development of rheumatoid arthritis (RA). We 
investigated if genetic variants in TLR genes are associated with RA and response to tumour necrosis factor blocking (anti- 
TNF) medication.
MethodologyandPrincipalFindings:22 single nucleotide polymorphisms (SNPs) in seven TLR genes were genotyped in a 
Dutch cohort consisting of 378 RA patients and 294 controls. Significantly associated variants were investigated in 
replication cohorts from The Netherlands, United Kingdom and Sweden (2877 RA patients and 2025 controls). 182 of the 
Dutch patients were treated with anti-TNF medication. Using these patients and a replication cohort (269 Swedish patients) 
we analysed if genetic variants in TLR genes were associated with anti-TNF outcome. In the discovery phase of the study we 
found a significant association of SNPs rs2072493 in TLR5 and rs3853839 in TLR7 with RA disease susceptibility. Meta-analysis 
of discovery and replication cohorts did not confirm these findings. SNP rs2072493 in TLR5 was associated with anti-TNF 
outcome in the Dutch but not in the Swedish population.
Conclusion: We conclude that genetic variants in TLRs do not play a major role in susceptibility for developing RA nor in 
anti-TNF treatment outcome in a Caucasian population.
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Introduction
Rheumatoid arthritis (RA) is a severe chronic inflammatory 
disorder leading to joint damage. The causes of RA are largely 
unknown, however, the role of genetic factors is evident, with the 
M HC region as the major contributor [1]. To date, more than 20 
non-M HC regions explaining approximately one third of the 
genetic contribution to RA have been identified [2].
The role of Toll-like receptors (TLRs) in the development of RA 
is supported by several studies. Synovial fibroblasts of RA patients 
constitutively express TLR  1-6, and it has been demonstrated that 
T LR  2, 3, 4 and 7 are up-regulated in RA synovial tissue compared 
to that of osteoarthritis patients and healthy controls [3]. 
Furthermore, the ligands for TLRs have been detected in synovium 
of RA patients [4] ,[5]. Since TLRs are potent activators of pro- 
inflammatory cytokines, including tumour necrosis factor (TNF)
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Table 1. Results of the case control association analysis in the Dutch discovery set.
gene chromosome SNP BP functional effect
major
allele
minor
allele
MAF
cases
MAF
controls
chi-
square p-value OR
9 5 %  CI 
interval
TLR2 4 rs1898830 154827903 Promoter ( — 15607) A G 0.34 0.33 0.05 0.83 1.03 0.81-1.30
rs5743704 154845401 Pro631His C A 0.04 0.05 n.a. n.a. n.a. n.a.
rs5743708 154845767 Arg753Gln G A 0.04 0.04 n.a. n.a. n.a. n.a.
TLR3 4 rs3775291 187241068 Leu412Phe C T 0.30 0.30 0.01 0.92 1.01 0.79-1.29
TLR4 9 rs4986790 119515123 Asp299Gly A G 0.05 0.05 0.003 0.96 0.99 0.60-1.63
rs4986791 119515423 Thr399Ile C T 0.05 0.05 0.003 0.96 0.99 0.60-1.63
rs7873784 119518757 3' UTR G C 0.18 0.16 0.54 0.46 1.12 0.83-1.51
TLR5 1 rs5744176 221350916 Asp694Gly A G 0 0 n.a. n.a. n.a. n.a.
rs5744174 221351151 Phe616Leu T C 0.47 0.46 0.12 0.73 1.04 0.83-1.30
rs2072493 221351222 Asn592Ser A G 0.10 0.15 6.35 0.01 0.64 0.46-0.91
rs5744168 221351823 Arg392STOP C T 0.08 0.07 0.74 0.39 1.21 0.78-1.88
rs764535 221352752 Thr82Ile G A 0.02 0.01 n.a. n.a. n.a. n.a.
TLR7 X rs2302267 12795499 Exon/intron boundary T G 0.05 0.04 n.a. n.a. n.a. n.a.
rs179008 12813580 Gln11Leu A T 0.21 0.24 0.94 0.33 0.86 0.63-1.17
rs5743781 12814891 Ala448Val C T 0 0.0003 n.a. n.a. n.a. n.a.
rs3853839 12817579 3' UTR C G 0.13 0.21 8.95 0.003 0.59 0.42-0.84
TLR8 X rs5741883 12834142 Promoter (—605) C T 0.24 0.22 0.69 0.41 1.14 0.84-1.55
rs3764879 12834618 Promoter ( — 129) C G 0.22 0.26 2.07 0.15 0.80 0.59-1.08
rs3764880 12834747 Exon (-3679) A G 0.22 0.26 1.87 0.17 0.81 0.60-1.10
rs5744088 12850485 3' UTR G C 0.16 0.13 1.49 0.22 1.26 0.87-1.82
TLR9 3 rs5743836 52235822 Promoter (-1237) A G 0.16 0.18 1.21 0.27 0.85 0.63-1.14
rs187084 52236071 Promoter (-1486) A G 0.41 0.43 0.49 0.48 0.92 0.73-1.16
MAF: minor allele frequency.
OR: odds ratio.
CI: confidence interval. 
n.a.: not analysed.
doi:10.1371/journal.pone.0014326.t001
alpha, this also makes them interesting candidates for treatment 
outcome prediction, especially for TNF-neutralizing therapy [6].
Several groups explored the contribution of genetic variants in 
TLR genes to the development of RA. A Korean study showed an 
association of a dinucleotide repeat in TLR2 with RA [7]. One 
other study focusing on two SNPs in TLR2 resulting in amino acid 
substitutions (Arg677Trp and Arg753Gln) could not detect an 
association between these rare variants and RA [8]. Although 
conflicting results have been reported on the functional variant 
Asp299Gly (rs4986790) in TLR4 most studies showed no 
association of this variant with RA susceptibility [8]—[13]. A 
French group investigated 10 SNPs in TLR1, 2, 4, 6 and 9 in 100 
families but did not find evidence for an association of variants in 
these genes with RA, autoantibody production or erosions [13]. A 
Turkish study, investigating variants in TLR3, 9 and 10 in 100 
patients, showed an association between a variant in TLR9 and 
RA susceptibility [14]. So far, only one small pharmacogenetic 
study on TLRs has been published [15]. The authors did not 
demonstrate an association between the Asp299Gly variant in 
TLR4 and the response to disease modifying anti-rheumatic drugs 
(DMARDs).
Although most studies performed to date point to a lack of 
association between genetic variants in genes coding for TLRs and 
RA disease susceptibility or treatm ent response, these have either 
been very small or did not comprehensively test potentially 
functional SNPs in the genes. Therefore we performed an
association study of TLRs testing involvement in RA pathogenesis 
and anti-TNF treatm ent response including seven TLR genes, 
three of which (TLR5, 7 and 8) have not been investigated in 
connection with RA before. The twenty-two SNPs investigated 
were selected for potential effects on gene function or regulation.
Results
Case control analysis
In the discovery phase of our study we included 378 RA patients 
and 294 controls and genotyped 22 SNPs in seven TLR genes. 
Genotyping failed for 51 samples (22 cases and 26 controls). Six 
SNPs were excluded from the analysis, based on a  low MAF 
(Table 1).
Two of the investigated polymorphisms, rs2072493 in TLR5 
and rs3853839 in TLR7, showed nominally significant allelic 
association with RA (p#0.01; Table 1). The minor allele of both 
SNPs conferred a  protective effect for the development of RA. A 
stratified analysis for either the shared epitope or rheumatoid 
arthritis. We did not identify SNPs that were specifically associated 
with one of the RA subgroups. The odds ratios for SNPs 
rs2072493 and rs3853839 were comparable to the odds ratios 
observed in the complete patient population (data not shown). The 
frequencies of rs2072493 and rs3853839 were investigated in three 
additional cohorts from The Netherlands, Sweden and the UK, 
consisting of 2877 patients and 2025 controls. This analysis
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TLR5 (rs2072493)
Study Df Subgroup
Patients 
Events Total
Controls 
Events Total
Odds Ratio 
Weight MH, Fixed, 95% Ci
Odds Ratio 
MH, Fixed, 95% Cl
Discovery Dutch 
Replication Dutch 
Replication Sweden 
Replication UK
Total (95% Cl)
Total events
71 712
88 624
562 4176
124 808
6320
78 532 13.2% 0.64[0.46,0.91]
157 1054 16.5% 0.94 J0.71,1.241
268 2090 50.9% 1.06(0.90,1.24]
144 860 19.4% 0.90(0.69,1.17]
4536 100.0% 0.95 10.85,1.07)
845 647
Heterogeneity: Chi’ s 6.87, df= 3 (P= 0.08); l*= 56% 
Test for overall effect Z = 0.84 (P = 0.40)
■+-
0.5 07 1
OR RA
1.5
TLR7 (rs3853839) females
Patients
Study or Subgroup
Controls Odds Ratio
Events Total Events Total Weight M-H, Random, 95% Cl
Odds Ratio 
M-H. Random, 95% Cl
Discovery Dutch 61 458 50 236 204% 0.57 [0.38, 0.86]
Replication Dutch 71 422 98 534 24.7% 0.90 [0.64,1.26]
Replication Sweden 522 2926 270 1538 36 6% 1 02 [0 87.1,20]
Replication UK 101 590 28 190 18 3% 1.20 [0.76,1.88]
Total (95% Cl) 4396 2498 100.0* 0.90(0.70,1.17)
Total events 
Heteroaeneih': Tau’ =
755 
0 04; Chi*= 7 63
446
df= 3 (P = 0.05); l*= 61% ---1----1---- ------- 1--- 1----
Test for overall effect Z = 0.76 (P = 0.44)
TLR7 (rs3853839) males
Patients Controls Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H. Random. 95% Cl
OR RA
Odds Ratio 
M-H, Random. 95% Cl
Discovery Dutch 17 127 29 148 20 4% 0.63 [0.33,1.22]
Replication Dutch 21 102 40 249 23.6% 1.35 [0.75,2.44)
Replication Sweden 116 599 45 266 38.9% 1.18 [0.81,1.72]
Replication UK 13 109 23 141 17.2% 0.69 [0.33,1.44]
Total (95% Cl) 937 804 100.0* 0.98(0.69,1.39)
Total events 167 137
Heterogeneity: Tau* =0 04, Chi*:: 4.56, df= 3 (P = 0.21); l*= 34%
Test for overall effect: Z= 0.11 (P = 0.91)
------ h
0.5 0.7 1 1.5 2 
OR RA
Figure 1. Meta-analysis of case control studies for TLR5 rs2072493 and TLR7 rs3853839.
doi:10.1371/journal.pone.0014326.g001
showed no association of the SNPs in TLR5 and TLR7 with RA 
aetiology either in the separate cohorts or in a  meta-analysis 
(Figure 1).
Anti-TNF treatment response
A subsample of the Dutch patients were treated with anti-TNF 
medication and had EULAR response information available at 3 
months (n = 182, Table 2). Results of the association analysis are 
shown in Table 3. TLR5 rs2072493 showed a significant 
association with anti-TNF treatm ent outcome (p = 0.003). In total, 
182 patients were included in the analysis. The EULAR response 
criteria were used to asses association of a genotype with anti-TNF 
response. The test statistic and p-value were from Fisher’s Exact 
Test for most SNPs, those indicated with * were based on Pearson 
Chi-square and p-value. A medication specific analysis showed 
that none of the investigated SNPs was associated with a  specific 
anti-TNF (Table S1). Validation of association found with TLR5 
in 269 RA patients treated with anti-TNF from Sweden did not 
confirm our initial findings (Fisher’s exact test p = 0.63).
The differences observed between the Dutch and Swedish 
cohort were not related to the anti-TNF used (Fisher’s exact test 
Swedish cohort for infliximab (p = 0.75) and etanercept (p = 0.49)).
Discussion
We found no evidence for association between 22 SNPs in TLR 
genes and RA disease susceptibility or anti-TNF treatment 
response, in keeping with the majority of the other candidate 
gene studies investigating TLRs in RA patients [7]—[13]. 
Furthermore, genome-wide association studies (GWAS) do not 
report associations between TLR genes and RA disease suscepti­
bility (www.genome.gov/gwastudies). Accessed December 31th 
2009), suggesting that genetic variants in these genes are not a 
major contributor to disease development [16]. However, some 
TLR  genes were poorly covered in the initial GWAS (e.g. no SNPs 
in TLR5 and 9 were included in these studies) [17],[18]. The TLR 
genes remain strong candidates for susceptibility genes in RA 
given their crucial role in mediating inflammatory signalling. One
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T ab le  2. Patient characteristics of RA patients treated with 
anti-TNF medication.
Cohort
The
Netherlands Sweden
Number of patients (N (%)) 182 (100) 269 (100)
Gender (female) 122 (67.0) 211 (78.4)
RF factor positive 141 (77.5)# 169 (88.9)##
MTX co-medication 105 (61.0)### 185 (68.8)
Anti-TNF medication
Adalimumab 61 (33.5) 0 (0)
Infliximab 118 (64.8) 156 (58.0)
Etanercept 3 (1.6) 113 (42.0)
Good response* 45 (24.7) 76 (28.3)
Moderate response* 92 (50.5) 137 (50.9)
No response* 45 (24.7) 56 (20.8)
DAS28 baseline (mean ± SD) 5.7261.16 5.8461.13
DAS28 3 months after treatment initiation
(mean ± SD)
4.1261.36 3.8961.30
^Response based on EULAR response criteria.
Data available for #180, ##190 and ###172 patients. 
doi:10.1371/journal.pone.0014326.t002
possibility is that these genes might harbour rare variants with 
large effect sizes, which would not be well tagged with the 
common SNPs selected for investigation in the current study. With 
the introduction of next generation sequencing technologies it 
should become possible to analyse the genes in a thorough manner 
but much larger sample sizes will be required to ensure power to 
detect association with rare variants, even if effect sizes are larger.
We could not identify an association of the investigated SNPs 
with anti-TNF response. We were unable to replicate the initial 
finding in the Dutch cohort. Differences in ethnicity, gender, RF 
and co-medication might influence the observed discrepancies. 
Besides the study has low power to detect an association due to the 
small patient population. Despite this the function of TLRs makes 
them likely candidate genes, since they directly modulate TNF 
expression [6]. In addition, De Rijcke and colleagues showed that 
anti-TNF treatm ent in spondylarthropathy results in a reduced 
expression of TLR2 and TLR4 [19]. The T LR  pathway should 
therefore be investigated in more detail before drawing definite 
conclusions about the contribution of these genes to anti-TNF 
treatm ent outcome.
In conclusion, our study does not support an association between 
genetic variants in TLR genes and RA disease susceptibility or anti- 
TN F treatment response.
Materials and Methods
Ethics Statement
The study was approved by the ethics committees of the 
participating institutions. For the Dutch samples the ‘‘Commissie 
Mensgebonden Onderzoek (CMO) Regio Arnhem Nijmegen’’ of 
the Radboud University Nijmegen Medical Centre approved the 
study (CMO number 2004/014). All Dutch patients and controls 
gave written informed consent prior to participation in the study. 
Verbal consent was received from all patients participating in the 
EIRA study and it was registered at clinical journals according to 
Swedish law. W ritten consent was received from healthy control 
individuals. The ethics committee of Karolinska Institutet
approved the study. All U K  patients and controls were recruited 
with ethical approval and provided written informed consent 
(North-West M ulti-Centre Research Ethics Committee (MREC 
99/8 /84) and the University of Manchester Committee on the 
Ethics of Research on H um an Beings).
Patients and controls
All patients in this study fulfilled the American College of 
Rheumatology (ACR) criteria. In  the discovery phase 378 Dutch 
RA patient participating in the Nijmegen Inception cohort and 
294 anonymous blood donors were included [20]. Cohorts from 
The Netherlands, Sweden and England were included in the 
replication phase. The Dutch replication cohort consisted of 313 
RA patients participating in the Dutch Rheumatoid Arthritis 
M onitoring (DREAM) registry [21]. The Dutch controls (n = 527) 
were part of the Nijmegen Biomedical Study [22].
The Swedish patients (n = 2158) and controls (sex, age and 
residence area matched, n =  1068) were part of the Epidemiolog­
ical Investigation of Rheumatoid arthritis (EIRA) study. The U K  
patients (n = 406) were recruited as part of the Arthritis Research 
Campaign National Repository of patients and families with one 
patient from each family selected for genotyping. U K  controls 
without a history of inflammatory arthritis (n = 430) were recruited 
from General Practitioner records or from blood donors.
Anti-TNF treatment outcome
Patients participating in the DREAM  registry were included in 
the study of anti-TNF treatment response. The registry includes 
patients with RA who start with anti-TNF treatment, according to 
the Dutch recommendations (Disease Activity Score (DAS28) 
>3.2  and previous failure on at least two disease-modifying 
antirheumatic drugs (DMARDs), one of which has to be 
methotrexate (MTX)) [21]. The DAS28 at treatm ent start and 
after 3 months of treatment were used to calculate the clinical 
response according to the EULAR criteria [23]. Association 
analysis was performed for the total patient group and a subgroup 
analysis for the patients treated with infliximab and adalimumab. 
Nominally significant findings (p#0.01) were validated in 269 anti- 
TNF treated RA patients from Sweden [23].
SNP genotyping
Twenty-two SNPs located in TLR2, 3, 4, 5, 7, 8 and 9 were 
genotyped in all Dutch patients and Dutch anonymous blood 
donors (Table 1). SNP selection criteria are described previously 
[24]. SNPs were genotyped using two multiplexed bead-based 
assays on a Luminex 100IS flow cytometer (Luminex Corporation, 
Austin, TX, USA). The tests were based on procedures previously 
described, with some modifications [24]-[26].
Replication studies were performed using TaqMan® SNP
genotyping assays for SNPs rs2072493 in TLR5 (assay ID C__
22273027_10) and rs3853839 in TLR7 (assay ID C___
2259573_10).
Statistical analysis
For quality control reasons we excluded SNPs that had a minor 
allele frequency (MAF) <0.05. Hardy-W einberg Equilibrium 
(HWE) was tested using the controls (only females were used for 
X-chromosomal SNPs), no deviations were observed. The whole 
genome association analysis toolset (PLINK) was used for 
association analysis at the allelic level [27]. A stratified analysis 
was performed for RF positive and negative as well as shared 
epitope positive and negative patients. SNPs with a nominal p- 
value #0.01 in the discovery sample were included in the
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T ab le  3. Results of the association analysis for anti-TNF treatment outcome after three months of treatment initiation.
Gene chromosome SNP Gender Test statistic p-value
TLR2 4 rs1898830 11.188* 0.024*
rs5743704 n.a. n.a.
rs5743708 n.a. n.a.
TLR3 4 rs3775291 7.74 0.096
TLR4 9 rs4986790 5.32 0.19
rs4986791 5.32 0.19
rs7873784 1.28 0.886
TLR5 1 rs5744176 n.a. n.a.
rs5744174 5.77 0.22
rs2072493 13.52 0.003
rs5744168 2.15 0.72
rs764535 n.a. n.a.
TLR7 X rs2302267 n.a. n.a.
rs179008 males not polymorph not polymorph
females 2.97* 0.24*
rs5743781 n.a. n.a.
rs3853839 males 4.69 0.089
females 4.61 0.27
TLR8 X rs5741883 males 0.87 0.75
females 3.34 0.51
rs3764879 males 1.41 0.48
females 1.76 0.85
rs3764880 males 1.41 0.48
females 1.76 0.85
rs5744088 males 0.63 0.80
females 3.20 0.50
TLR9 3 rs5743836 2.98 0.63
rs187084 0.61 0.97
In total, 182 patients were included in the analysis. The EULAR response criteria were used to asses association of a genotype with anti-TNF response. The test statistic 
and p-value were from Fisher's Exact Test for most SNPs, those indicated with * were based on Pearson Chi-square and p-value. SNPs located on the X-chromosome 
were analysed for males and females separately. 
doi:10.1371/journal.pone.0014326.t003
replication phase. Review Manager 5 (Review M anager (RevMan) 
Version 5.0. Copenhagen: The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2008) was used to perform a meta­
analysis. Homogeneity of odds ratios (OR) among cohorts was 
calculated using the Breslow-Day method, and pooled ORs were 
calculated under a fixed effects model (Mantel-Haenszel meta­
analysis).
To assess the effect of SNPs on anti-TNF response, a two-tailed 
Fisher’s exact or Chi-square test was used (where applicable) for 
the comparison of the EULAR response scores between the three 
genotype groups in a 3x 3  table in SPSS (SPSS for Windows, 
version 16.0). X-chromosomal SNPs were analyzed for males and 
females separately.
Supporting Information
Table S1 Results of the association analysis for anti-TNF 
treatment outcome after three months of treatment initiation.
Found at: doi:10.1371/journal.pone.0014326.s001 (0.07 MB 
DOC)
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